EPI or exocrine pancreatic insufficiency is a medical condition which is characterized by deficiency of the enzymes of exocrine pancreatic. This hampers their ability to process food effectively. It is also called as maldigestion. A study by Transparency Market Research (TMR) incorporates key market information, for example, drivers, restrictions, and various growth opportunities in the forecast years influencing the demand for exocrine pancreatic insufficiency (EPI) treatment tools and devices. The rising occurrence of medical conditions, for example, chronic pancreatitis, cystic fibrosis, and diabetes are adding to the rising demand for viable treatment for exocrine pancreatic insufficiency across the world, as the condition is diagnosed frequently in the people suffering from cystic fibrosis. As indicated by the Cystic Fibrosis Foundation, almost 70,000 individuals are suffering with cystic fibrosis over the globe. Out of these, 30,000 are in the U.S. itself. In the U.S., about 1,000 new instances of the condition are analysed each year, thereby increasing the danger of exocrine pancreatic insufficiency.
The rising cases of exocrine pancreatic insufficiency are likewise also attributable to the increasing number of diabetic people over the globe. Diabetic patients are at a higher risk of inflammation and harm to the pancreatic tissue, which in turn can lead to exocrine pancreatic insufficiency. The growth in the number of people suffering from of diabetes worldwide is expected to be a key driver of the global exocrine pancreatic insufficiency market in the next couple of years. Developing economies, particularly in Asia Pacific region, which are home to the world’s biggest pool of diabetics – and the numbers are continually rising – will serve to majorly fuel the market for exocrine pancreatic insufficiency, predict experts.
The pancreatic compound substitution treatment section has been sub-fragmented into Creon, Zenpep, Pancreaze, Ultresa, Viokace, and Pertzye. Creon held the biggest share in the EPI market in the U.S. in 2014 and is foreseen to lead this market in the following couple of years. Apart from that, Ultresa is expected to rise at the most noteworthy rate as it is more technologically advanced compared to other forms of pancreatic enzyme replacement therapy. Ultresa, in the past known as ‘Ultrase’, is an orally administered porcine pancreatic enzyme preparation (PEP) that was already used for the treatment of EPI in grown-ups and kids. The market for Ultresa is probably going to grow at the most noteworthy rate because of high uptake by patients and as it gives a compelling treatment choice to the patient. The exocrine pancreatic deficiency market in relation to the medical domain has been fragmented as pancreatic enzyme replacement treatment (PERT) drugs and medical tests for diagnosing the disease.
Request Sample of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2748
Geographically, the exocrine pancreatic deficiency market has been categorized into five noteworthy regions which are Asia Pacific, North America, Europe, Latin America and the Rest of the World. In addition, analysis of the huge nations containing U.S. Canada, U.K., Germany, China, Japan, Brazil, Russia, South Africa and Mexico have been given in the report too. A thorough qualitative analysis of the variables in charge of driving and controlling the development of the exocrine pancreatic deficiency market in different regions has been given in the report.
The players that are profiled in the report are Allergan plc, AzuRx Biopharma Inc, Anthera Pharmaceuticals Inc, Abbvie Inc., Cilian AG, and Digestive Carew Inc. They are among the most dominant ones that are investing heavily and reigning in the global market exocrine pancreatic insufficiency market.